Memantine Dawa

Memantine Hydrochloride, the active ingredient in Memantine Dawa, is a NMDA receptor antagonist presented as an oral dosage form for oral use. It is indicated for the treatment of moderate to severe Alzheimer’s disease in adult patients, helping to improve cognition and functional abilities.

GNH USA supplies Memantine Dawa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution, ensuring product integrity throughout the supply chain.

Memantine Dawa is used in the management of neurodegenerative conditions affecting cognition, primarily within the Alzheimer’s disease spectrum.

- Moderate to severe Alzheimer’s disease: improves cognitive function and daily living activities in affected patients. - Dementia associated with Alzheimer’s disease: helps slow the progression of memory loss and functional decline. - Behavioral symptoms of Alzheimer’s disease: may reduce agitation, aggression and other neuropsychiatric manifestations.

Memantine Dawa may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Fatigue

Serious or Rare Side Effects: - Seizures - Severe allergic reactions (e.g., rash, angioedema) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Hepatotoxicity (elevated liver enzymes)

When prescribing Memantine Dawa, clinicians should consider several precautionary measures to ensure safe use.

- Renal impairment: adjust dose or monitor renal function in patients with reduced clearance. - Hepatic impairment: use with caution and assess liver function regularly. - History of seizures: monitor closely as the drug may lower seizure threshold. - Concomitant NMDA antagonists: avoid combined use to reduce risk of additive CNS effects. - Pregnancy and lactation: safety not established; weigh potential benefits against unknown risks. - Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and direct sunlight.

Memantine Dawa can interact with other medicines, influencing its plasma levels or combined pharmacodynamic effects.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase central nervous system adverse effects. - Ketoconazole: strong CYP3A4 inhibition can raise memantine concentrations. - Rifampin: potent CYP3A4 induction may reduce memantine exposure.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish the cognitive benefits of memantine. - Diuretics: can affect blood pressure and electrolyte balance when combined. - Other CNS depressants (e.g., benzodiazepines): may enhance dizziness or sedation.